Intranasal Peptide Administration: Complete Guide

Most peptide researchers default to subcutaneous injection without ever considering that for certain compounds, a nasal spray can deliver comparable—or even superior—results. A 2018 study published in Pharmaceutical Research demonstrated that intranasal insulin reached cerebrospinal fluid concentrations 7-fold higher than intravenous delivery at equivalent doses, challenging the long-held assumption that injection is always the gold standard. For a specific subset of peptides, the nose-to-brain pathway offers a direct route that bypasses first-pass metabolism and, in some cases, the blood-brain barrier itself.

This guide covers the science behind intranasal peptide delivery, which peptides are best suited for it, practical preparation techniques, and the bioavailability data researchers should know before choosing their administration route.

The Science Behind Intranasal Delivery

The nasal cavity is far more than a simple air passage. The upper nasal epithelium contains the olfactory region—a roughly 10 cm² area in humans—where olfactory sensory neurons project directly through the cribriform plate into the brain's olfactory bulb. This anatomical shortcut is the foundation of nose-to-brain drug delivery, a concept that has gained significant traction in neuroscience research over the past two decades.

There are three primary transport pathways for intranasally administered compounds. The first is the olfactory nerve pathway, where molecules are transported along olfactory neurons via intracellular or extracellular mechanisms to reach the olfactory bulb and, from there, deeper brain structures. The second is the trigeminal nerve pathway, which innervates the respiratory epithelium of the nasal cavity and projects to the brainstem, providing another direct route to the central nervous system. The third is systemic absorption through the richly vascularized nasal mucosa, which functions similarly to an injection by delivering the peptide into general circulation.

For peptides that target the central nervous system—nootropics, anxiolytics, neuroprotective agents—the first two pathways are particularly valuable. Research by Lochhead and Thorne (2012) demonstrated that intranasal delivery of large molecules including peptides and proteins can achieve brain concentrations that would require orders-of-magnitude higher systemic doses to match. This is why intranasal Semax, Selank, and oxytocin have become subjects of intense research interest.

Bioavailability: Intranasal vs. Injection

Bioavailability is the critical variable when comparing administration routes, and the data varies enormously depending on the peptide in question. Small, relatively lipophilic peptides tend to perform well intranasally, while larger peptides face significant absorption barriers.

The nasal mucosa presents several challenges to peptide absorption: mucociliary clearance sweeps compounds toward the nasopharynx within 15–20 minutes, enzymatic degradation by aminopeptidases and proteases in the nasal epithelium can break down peptides before they absorb, and the tight junctions between epithelial cells restrict paracellular transport of molecules larger than roughly 1,000 Daltons.

The pattern is clear: peptides under roughly 1,000 Da with some degree of lipophilicity tend to perform best intranasally. Semax and Selank were specifically developed with nasal delivery in mind by Russian pharmaceutical researchers, which partly explains their strong intranasal performance. Larger peptides like BPC-157 and most growth hormone secretagogues lack the absorption profile that would make intranasal delivery practical without absorption enhancers.

Best Peptides for Intranasal Administration

Not every peptide is a candidate for nasal delivery. Based on the available research literature and community experience, here are the peptides most commonly and successfully used via the intranasal route.

Semax and NA-Semax

Semax is arguably the poster child for intranasal peptide delivery. Developed at the Institute of Molecular Genetics in Russia, it was designed from the outset as a nasal spray. Semax is a synthetic analog of ACTH(4-10) with a modified C-terminus that improves stability against enzymatic degradation. Its primary researched effects include upregulation of BDNF expression, modulation of serotonergic and dopaminergic systems, and neuroprotection against oxidative stress. The N-acetyl variant (NA-Semax) adds an acetyl group that further enhances stability and may increase potency. Research dosing in the literature typically ranges from 200–600 mcg per administration, delivered 1–3 times daily.

Selank and NA-Selank

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, also developed at Russian research institutes. It has been studied primarily for anxiolytic and nootropic effects, with research demonstrating modulation of GABA-A receptor expression, influence on IL-6 and monoamine metabolism, and a favorable safety profile in preclinical models. Like Semax, it was designed for intranasal use. Reported intranasal bioavailability of 60–80% makes it one of the best-absorbing nasal peptides studied. The N-acetyl form (NA-Selank) offers enhanced enzymatic stability and a potentially prolonged duration of action.

Oxytocin

Intranasal oxytocin has been the subject of hundreds of clinical studies investigating its effects on social cognition, anxiety, trust, and bonding. While systemic bioavailability via the nose is quite low (2–5%), the clinical effects observed in trials strongly suggest meaningful CNS delivery through direct nose-to-brain pathways. Research protocols typically use 20–40 IU delivered via calibrated nasal spray devices. Notably, a 2020 systematic review in Psychoneuroendocrinology found that intranasal oxytocin produced measurable behavioral and neuroimaging effects in the majority of controlled trials, supporting the viability of this delivery route for this particular peptide.

Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small angiotensin IV analog that has shown remarkable potency in preclinical cognitive research. Its relatively small size and lipophilic hexanoyl group make it theoretically amenable to nasal absorption. Some researchers have explored intranasal delivery, though published bioavailability data specifically for this route remains limited. The compound's potency at picomolar concentrations means that even modest nasal absorption may be functionally relevant.

How to Prepare a Peptide Nasal Spray

Preparing a nasal spray from lyophilized peptide requires attention to sterility, accurate dosing calculations, and appropriate equipment. The following outlines the standard laboratory preparation method documented in research protocols.

Equipment Needed

Researchers typically use a sterile metered-dose nasal spray bottle (most deliver 0.1 mL per actuation), bacteriostatic water (BAC water) as the reconstitution solvent, alcohol swabs for vial tops, and standard syringes for transfer. Some protocols call for sterile saline (0.9% NaCl) instead of BAC water, particularly for sensitive compounds or when benzyl alcohol preservative is a concern.

Dosing Calculations

The math is straightforward but important to get right. If a nasal spray bottle delivers 0.1 mL per pump, and the target dose is 300 mcg per spray, the required concentration is 3 mg/mL (3,000 mcg per mL). For a 5 mg vial of peptide, reconstituting with 1.67 mL of BAC water would yield approximately 3 mg/mL. Most researchers round to convenient volumes and adjust the number of sprays per dose accordingly.

Preparation Steps

The general laboratory protocol involves first cleaning the peptide vial septum with an alcohol swab, then slowly adding the calculated volume of BAC water, directing it down the side of the vial rather than directly onto the lyophilized powder to avoid degradation from mechanical stress. After gentle swirling (never shaking) until fully dissolved, the solution is drawn up and transferred into the nasal spray bottle through the opening or via syringe. The priming process—pumping the spray several times until a consistent mist is produced—wastes a small amount of solution, which should be factored into the initial volume calculation.

Proper Intranasal Administration Technique

Technique matters more than most researchers realize. Poorly executed nasal administration can reduce effective delivery by 50% or more, with the majority of the dose draining into the throat and being swallowed rather than absorbing through the nasal mucosa.

Research protocols consistently emphasize several technique elements. First, gentle nose-clearing before administration removes excess mucus that acts as a barrier. However, aggressive blowing should be avoided as it can cause transient mucosal inflammation. Second, the head should be tilted slightly forward (not back), with the spray bottle angled slightly outward toward the lateral nasal wall rather than aimed at the septum. This targets the more absorptive lateral epithelium and avoids the less vascularized septal cartilage area.

Third, a gentle sniff during actuation—not a sharp inhalation—helps distribute the spray across the upper nasal cavity without drawing it too quickly into the nasopharynx. Fourth, alternating nostrils between sprays distributes the dose more evenly and avoids saturating one side's absorptive capacity. Finally, remaining upright and avoiding nose-blowing for at least 10–15 minutes after administration gives the peptide time to absorb before mucociliary clearance sweeps the remaining solution posteriorly.

Absorption Enhancers and Formulation Strategies

For peptides with naturally poor nasal absorption, pharmaceutical research has identified several strategies to improve bioavailability. These are primarily relevant to laboratory formulation work rather than standard reconstitution practices.

Cyclodextrins, particularly hydroxypropyl-beta-cyclodextrin, have been shown to improve nasal peptide absorption by 2–5-fold in some studies. They work by transiently increasing membrane permeability and protecting peptides from enzymatic degradation. Chitosan, a biopolymer derived from chitin, is another well-studied absorption enhancer that works by temporarily opening tight junctions between epithelial cells. Research published in the Journal of Controlled Release demonstrated that chitosan-formulated nasal insulin achieved bioavailability roughly 3 times higher than insulin in simple saline solution.

Other investigated enhancers include alkylsaccharides (particularly dodecyl maltoside, used in the FDA-approved Valtoco diazepam nasal spray), bile salts, phospholipids, and cell-penetrating peptides. However, it is worth noting that many absorption enhancers carry a trade-off: they can cause nasal mucosal irritation with repeated use, which may paradoxically reduce long-term absorption and raises safety questions for chronic administration protocols.

Stability and Storage Considerations

Peptide stability in nasal spray formulation is a practical concern that directly affects research outcomes. Once reconstituted in aqueous solution, peptides are significantly more vulnerable to degradation than in their lyophilized form. Temperature, pH, oxidation, and microbial contamination are the primary threats.

Most reconstituted peptide nasal sprays should be stored refrigerated at 2–8°C. Bacteriostatic water provides some antimicrobial protection via its benzyl alcohol content, but this is not a substitute for proper refrigeration and sterile handling. Research groups typically prepare only enough solution for 2–4 weeks of use, discarding and preparing fresh solution afterward. Some peptides, particularly those containing methionine residues, are susceptible to oxidation and may benefit from nitrogen-purged vials and light-protected storage.

Importantly, the nasal spray device itself introduces stability variables. The plastic and rubber components of spray pumps can adsorb peptides from solution, potentially reducing concentration over time. This effect is most pronounced with hydrophobic peptides and at low concentrations. Researchers investigating this issue have found that glass vials with PTFE-coated spray pumps minimize adsorptive losses compared to standard plastic devices.

When to Choose Intranasal vs. Injection

The decision between intranasal and injectable administration should be driven by the specific peptide, the research target, and practical considerations. Neither route is universally superior.

Intranasal delivery is clearly preferred for CNS-targeting peptides like Semax, Selank, and oxytocin, where direct nose-to-brain transport provides a pharmacological advantage that injection cannot replicate. For these compounds, the nasal route is not a compromise—it is the optimal delivery method supported by the design of the peptides themselves and the weight of the published literature.

Injectable administration remains the clear choice for systemic peptides like BPC-157, TB-500, growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-2/6), and any peptide where peripheral tissue exposure is the primary research target. The bioavailability advantage of subcutaneous injection (typically 65–100% depending on the peptide) far exceeds what nasal delivery can achieve for most of these compounds.

There is a gray zone for peptides where both routes have some supporting data but neither is definitively established as superior. In these cases, researchers should weigh factors including the specific tissue target, the importance of CNS versus systemic exposure, subject compliance considerations (nasal sprays are less invasive), and the available pharmacokinetic data for each route with the specific compound in question.

Limitations and Practical Challenges

Intranasal peptide delivery is not without its challenges, and researchers should be aware of several practical limitations that can affect experimental outcomes.

Nasal congestion, allergies, and upper respiratory infections can dramatically reduce absorption. Even mild mucosal inflammation alters the permeability characteristics of the nasal epithelium in unpredictable ways. Seasonal allergy sufferers may see significant variability in peptide absorption throughout the year. Additionally, the use of nasal decongestant sprays (oxymetazoline, phenylephrine) causes vasoconstriction that can reduce peptide absorption by limiting blood flow to the absorptive mucosa.

Dose reproducibility is another challenge. Unlike injection, where the delivered dose is precisely controlled by the syringe volume, nasal spray delivery has inherent variability. Metered-dose pumps typically have a ±10–15% coefficient of variation in output volume, and individual differences in nasal anatomy, mucus production, and technique introduce further variability. For research requiring tight dose control, this imprecision may be problematic.

Finally, the total volume that can be administered intranasally is limited. Each nostril can effectively absorb roughly 150–200 µL before runoff occurs, setting a practical ceiling of about 400 µL per administration event. For peptides requiring high doses, this volume constraint may necessitate highly concentrated formulations or multiple dosing events spaced apart, both of which introduce their own challenges.

Frequently Asked Questions